SM-102 792885 heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate

SM-102, a synthetic ionizable lipid with a pKa of 6.68, can be used in combination with other lipids to formulate lipid nanoparticles (LNPs) for drug delivery applications. mRNA delivery via LNPs formulated with SM-102 show good efficiency and accumulation primarily in the liver.

SM-102 is most known as a component of mRNA-based COVID-19 vaccines but has also been, and continues to be, studied for delivery of other payloads and various applications. Below is a sample of studies conducted using formulations containing SM-102:

• Peptide-conjugated PLK1-targeted siRNA delivery across the blood-brain barrier for treatment of glioblastoma multiforme.¹
• Transfection of dendritic cells with circular RNA (circRNA) vaccines to elicit T cell responses.²
• Delivery of ribonucleoproteins (RNPs) for in vivo genome editing.³

Product is provided for Research Use Only intended for seeking Food and Drug Administration’s (FDA) approval under The Hatch-Waxman Act (formally known as the Drug Price Competition and Patent Term Restoration Act of 1984).

This product is available for shipping within the United States only. International shipping is not available.

References:

1. Haiyang Tong, Zesen Ma, Jin Yu, Dongsheng Li, Qingjun Zhu, Huajian Shi, Yun Wu, Hongyi Yang, Yanmin Zheng, Demeng Sun, Pan Shi, Jiaru Chu, Pei Lv, Baoqing Li, and Changlin Tian. ACS Chemical Biology 2025 20 (4), 942-952. DOI: 10.1021/acschembio.5c00039
2. Yasir Alshehry, Xiang Liu, Yu Zhang, Guizhi Zhu. Journal of Controlled Release2025 381. DOI: 10.1016/j.jconrel.2025.113617
3. Hołubowicz, R., Du, S.W., Felgner, J. et al. Nat. Biomed. Eng 9, 57–78 (2025). DOI: 10.1038/s41551-024-01296-2